COMP <GO>
QTTB vs LLY // GROSS PROFIT MARGIN
Q32 Bio Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: QTTB 4
— LLY 7
■ METRIC PARITY
LAST: $8.87 (-2.10%) • MKT CAP: $264.1M
gross-margins
—
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
gross-margins
83.64%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (QTTB VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | QTTB | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | 83.64% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 32.36% | +52.64 | QTTB | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.8x | 36.4x | -23.62 | QTTB | /valuation <GO> |
| Free Cash Flow Yield | -12.70% | 2.30% | -15.00 | LLY | /fcf-yield <GO> |
| Operating Margin | 31.50% | 40.21% | -8.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | 55.50% | 31.90% | +23.60 | QTTB | /net-margins <GO> |
| Revenue Growth (YoY) | — | 45.51% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.99 | 9.29 | -3.30 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 9/9 | -5.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.1 | 66.6 | -18.48 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.3x | 26.3x | -17.95 | QTTB | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $264.1M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | QTTB REV | LLY REV | QTTB GROSS % | LLY GROSS % | QTTB FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $53.7M | $65.18B | — | 83.0% | -$33.5M | $16.81B |
| FY 2024 | $0 | $45.04B | — | 81.3% | -$67.8M | $8.82B |
| FY 2023 | $1.2M | $34.12B | — | 79.3% | -$18.7M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
QTTB // BETA —
LLY // BETA 0.51